-
公开(公告)号：US4614793A
公开(公告)日：1986-09-30
申请号：US585942
申请日：1984-03-02
CPC分类号： C07K14/005 , C07K16/1009 , A61K38/00 , A61K39/00 , C12N2770/32422 , C12N2770/32434 , Y10S530/806 , Y10S530/826 , Y10S930/223
摘要： A surface structural protein of Hepatitis A Virus (HAV) has been isolated and characterized from virus grown in tissue culture. This 33,000 dalton viral protein (VP-1) reacts with immune HAV sera and monoclonal antibodies that neutralize HAV infectivity. The VP-1 is usable for the preparation of a polypeptide subunit vaccine for HAV.Hybridoma cells were made which produced monoclonal antibodies to HAV or VP-1. These monoclonal antibodies were found to neutralize the infectivity of HAV and to compete with polyclonal antibody derived from human HAV immune sera. The monoclonal antibodies are useful for the neutralization of infectious HAV, the detection of antibodies to neutralizing sites on HAV, and the diagnoses of HAV disease in humans and other susceptible hosts.
摘要翻译： 甲型肝炎病毒（HAV）的表面结构蛋白已经从在组织培养物中生长的病毒分离并表征。 该33,000道顿病毒蛋白（VP-1）与免疫HAV血清和中和HAV感染性的单克隆抗体反应。 VP-1可用于制备HAV的多肽亚单位疫苗。 制备产生单克隆抗体HAV或VP-1的杂交瘤细胞。 发现这些单克隆抗体中和HAV的感染性并与来自人HAV免疫血清的多克隆抗体竞争。 单克隆抗体可用于感染性HAV的中和，HAV中和位点的抗体检测以及人类和其他敏感宿主中HAV病的诊断。
-
公开(公告)号：US5258401A
公开(公告)日：1993-11-02
申请号：US938981
申请日：1992-09-10
IPC分类号： C07D493/08 , A61K31/335 , A61K31/34 , A61K31/365 , A61K31/38 , C07D319/04 , C07D405/06 , C07D405/08 , C07D407/06
CPC分类号： C07D493/08
摘要： Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.
摘要翻译： 本文公开了可用作降胆固醇剂的结构式（I）化合物（I）。 这些化合物也可用作角鲨烯合酶抑制剂，真菌生长抑制剂，法呢基蛋白转移酶抑制剂和致癌基因蛋白Ras的法呢基化。 这些化合物也可用于治疗癌症。
-
公开(公告)号：US06177404B1
公开(公告)日：2001-01-23
申请号：US09051759
申请日：1998-08-03
申请人： Deborah DeFeo-Jones , Raymond E. Jones , Allen I. Oliff , Edward M. Scolnick , Victor M. Garsky
发明人： Deborah DeFeo-Jones , Raymond E. Jones , Allen I. Oliff , Edward M. Scolnick , Victor M. Garsky
IPC分类号： A61K3816
CPC分类号： A61K47/65
摘要： Novel pharmaceutical compositions useful for the treatment of benign prostatic hyperplasia which comprises novel oligopeptides, which are selectively cleaved by enzymatically active PSA, in conjugation with a cytotoxic agent are described. Methods of treating benign prostate hypertrophy are also disclosed.
摘要翻译： 描述了可用于治疗良性前列腺增生的新型药物组合物，其包含通过酶活性PSA选择性切割的与细胞毒性剂缀合的新型寡肽。 还公开了治疗良性前列腺肥大的方法。
-
公开(公告)号：US5663195A
公开(公告)日：1997-09-02
申请号：US646604
申请日：1996-05-08
申请人： Edward M. Scolnick
发明人： Edward M. Scolnick
IPC分类号： A61K31/00 , A61K31/365 , A61K31/4709 , A61K31/34
CPC分类号： A61K31/4709 , A61K31/00 , A61K31/365
摘要： The invention encompasses a method of inhibiting bone resorption in patients in need of such inhibition to a degree sufficient to halt or retard loss of bone mass, reduce fractures, improve bone repair and prevent or treat osteoporosis comprising: the administration of a non-toxic therapeutically effective amount of a selective cyclooxygenase-2 inhibitor such as the compounds of formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for the purposes described above.
摘要翻译： 本发明包括一种在需要这种抑制的患者中抑制骨吸收的方法，其程度足以停止或延缓骨量的减少，减少骨折，改善骨修复和预防或治疗骨质疏松症，其包括：治疗 有效量的选择性环氧合酶-2抑制剂，例如式I化合物。本发明还包括用于上述目的的某些药物组合物。
-
公开(公告)号：US4952561A
公开(公告)日：1990-08-28
申请号：US688798
申请日：1985-01-04
IPC分类号： G01N33/68 , A61K35/74 , A61K38/00 , A61K38/22 , A61P9/00 , A61P9/12 , C07K7/08 , C07K14/00 , C07K14/575 , C07K14/58 , C12N1/20 , C12N15/09 , C12P21/00 , C12P21/02 , C12R1/19
摘要： A DNA fragment encoding at least part of the ANF protein has been molecularly cloned and its nucleotide sequence partially determined. The composition and sequence of a peptide containing 116 amino acids within the ANF gene have been determined. Biologically active subunit peptides have been identified.
摘要翻译： 编码至少部分ANF蛋白的DNA片段已经被分子克隆，并且部分确定其核苷酸序列。 已经确定了ANF基因内含有116个氨基酸的肽的组成和序列。 生物活性亚单位肽已被鉴定。
-
公开(公告)号：US4707542A
公开(公告)日：1987-11-17
申请号：US636514
申请日：1984-08-01
申请人： Arthur Friedman , E. Dale Lehman , William J. McAleer , Ted F. Schaefer , Edward M. Scolnick , D. Eugene Wampler
发明人： Arthur Friedman , E. Dale Lehman , William J. McAleer , Ted F. Schaefer , Edward M. Scolnick , D. Eugene Wampler
CPC分类号： C07K14/005 , A61K39/12 , A61K39/292 , A61K2039/55505 , A61K39/00 , C12N2730/10122 , C12N2730/10134 , Y10S435/803 , Y10S436/82 , Y10S530/806 , Y10S530/826
摘要： The surface antigen protein of human Hepatitis B virus is synthesized in Saccharomyces cerevisiae as a 23,000-26,000 dalton polypeptide, essentially free of intermolecular disulfide bonds. This antigen is a poor immunogen in animals and man. No prior precedent or method exists for efficiently converting the non-disulfide bonded antigen to a fully intermolecular disulfide bonded particle. We describe the first example of such a conversion in vitro and show that the act of this conversion enhances the immunogenicity of the antigen about 10-fold. The in vitro conversion makes practical the production of hepatitis B surface antigen from microorganisms using recombinant DNA methods.
摘要翻译： 人类乙型肝炎病毒的表面抗原蛋白在酿酒酵母中合成为23,000-26,000道尔顿多肽，基本上不含分子间二硫键。 这种抗原是动物和人类的不良免疫原。 没有先前的先例或方法有效地将非二硫键合抗原转化成完全分子间二硫键合的颗粒。 我们在体外描述了这种转化的第一个例子，并表明这种转化的作用增强了抗原的免疫原性约10倍。 体外转化使得使用重组DNA方法从微生物生产乙型肝炎表面抗原成为可能。
-
公开(公告)号：US5376383A
公开(公告)日：1994-12-27
申请号：US13111
申请日：1993-02-01
IPC分类号： A61K9/00 , A61K9/20 , A61K31/00 , A61K31/215 , A61K31/22 , A61K31/365 , A61K9/24
CPC分类号： A61K31/22 , A61K31/00 , A61K31/215 , A61K31/365 , A61K9/0004 , A61K9/2054
摘要： The instant invention is directed to a method for enhancing the lowering of plasma cholesterol level in a subject in need thereof which comprises the time-controlled administration of a nontoxic therapeutically effective amount of an HMG-CoA reductase inhibitor to said subject which surprisingly affords an equivalent or improved reduction of plasma cholesterol levels while significantly reducing the amount of HMG-CoA reductase inhibitor circulating in the bloodstream of the subject as compared to the same parameters when the oral administration of a conventional rapid release dosage form is utilized.
摘要翻译： 本发明涉及用于增强有需要的受试者中血浆胆固醇水平降低的方法，其包括将无毒治疗有效量的HMG-CoA还原酶抑制剂时间控制施用于所述受试者，令人惊讶地提供相当于 或者当使用常规的快速释放剂型的口服给药时，与相同的参数相比，血浆胆固醇水平的改善降低，同时显着减少在受试者的血液中循环的HMG-CoA还原酶抑制剂的量。
-
公开(公告)号：US5310668A
公开(公告)日：1994-05-10
申请号：US846751
申请日：1992-02-27
IPC分类号： A61K39/00 , A61K39/295 , C07K14/02 , C07K14/03 , C12N15/869 , C12N15/86 , A61K39/25 , C12N7/01
CPC分类号： C12N15/86 , A61K39/12 , C07K14/005 , A61K2039/70 , A61K39/00 , C12N2710/16234 , C12N2710/16722 , C12N2710/16734 , C12N2710/16743 , C12N2730/10122
摘要： A vaccine strain of varicella-zoster virus (VZV), tested in clinical trials, is capable of preventing chickenpox in children. This virus has been modified by the introduction into its genome of heterologous DNA which encodes an immunogenic polypeptide of another human pathogen. This heterologous polypeptide is expressed in cells infected by the recombinant virus. Such recombinant VZV is useful as a vaccine for chickenpox as well as for heterologous pathogens.
摘要翻译： 在临床试验中测试的水痘带状疱疹病毒疫苗株（VZV）能够预防儿童中的水痘。 该病毒已经通过引入其编码另一人类病原体的免疫原性多肽的异源DNA的基因组进行了修饰。 该异源多肽在由重组病毒感染的细胞中表达。 这种重组VZV可用作水痘疫苗以及异源病原体。
-
公开(公告)号：US4997658A
公开(公告)日：1991-03-05
申请号：US274173
申请日：1988-11-21
IPC分类号： A61K9/00 , A61K9/28 , A61K31/00 , A61K31/215 , A61K31/365 , A61K45/00 , A61K45/08 , A61M37/00 , A61P3/06 , A61P9/10 , A61P43/00
CPC分类号： A61K9/0004 , A61K31/00 , A61K31/215 , A61K31/365
摘要： The instant invention is directed to a method for enhancing the lowering of plasma cholesterol level in a subject in need thereof which comprises the time-controlled administration of a nontoxic therapeutically effective amount of an HMG-CoA reductase inhibitor to said subject which surprisingly affords an equivalent or improved reduction of plasma cholesterol levels while significantly reducing the amount of HMG-CoA reductase inhibitor circulating in the bloodstream of the subject as compared to the same parameters when the oral administration of a conventional rapid release dosage form is utilized.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.02 秒)